Voltar
Artigo Revisado por pares
BIBTEX RIS

Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study

2024; Elsevier BV; Volume: 7; Issue: 3 Linguagem: Inglês

10.1016/j.euo.2023.12.013

ISSN

2588-9311

Autores

Hideaki Miyake, Rikiya Matsumoto, Kiyohide Fujimoto, Atsushi Mizokami, Hirotsugu Uemura, Toshiyuki Kamoto, Satoru Kawakami, Kazuyoshi Nakamura, Shigekatsu Maekawa, Kazuhiro Shibayama, Aki Watanabe, Miku Ito, Yohei Tajima, Hideyasu Matsuyama, Hiroji Uemura,

Tópico(s)

Radiopharmaceutical Chemistry and Applications

Resumo

Androgen deprivation therapy (ADT), administered alone, as combined androgen blockade (CAB) or as ADT plus androgen receptor signalling inhibitors (ARSIs) or ADT plus docetaxel, is the standard treatment for metastatic hormone-naïve prostate cancer (mHNPC) in Japanese real-world practice.

Referência(s)